News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promethera Raises $31.4 Million to Progress Progenitor Cell Therapy for Liver Diseases



3/29/2012 7:13:42 AM

Belgian cell therapy firm Promethera Biosciences raised €23.6 million (about $31.4 million) in a Series B round of financing. The funds come in the form of €17 million in capital from a group of five new investors, and a €6.6 million loan from the regional Walloon investment body, which has backed Promethera since its establishment in 2009. Promethera is a spin-out from the Université Catholique de Louvain (UCL), which is developing allogeneic adult stem cell therapies for liver diseases. The firm is currently focused on two products based on the recently discovered heterologous human adult liver progenitor cells (HHALPCs). Promethera HepaStem is an early-clinical-stage injectable cell therapy designed to treat severe genetic liver diseases in children and adults, and in particular Crigler-Najjar syndrome, urea cycle disorders, phenylketonuria, and glycogenosis Type-1.



comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES